Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients

Transplantation

Volumn 93, Issue 11, 2012, Pages 1075-1085

  Nashan, Björn ^a   Gaston, Robert ^b   Emery, Vincent ^c   Säemann, Marcus D ^d   Mueller, Nicolas J ^e   Couzi, Lionel ^f   Dantal, Jacques ^g   Shihab, Fuad ^h   Mulgaonkar, Shamkant ⁱ   Seun Kim, Yu ^j   Brennan, Daniel C ^k  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ Saint Barnabas Health Care System   (United States)

^j Yonsei University College of Medicine   (South Korea)

^k WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Anti CMV mechanism of action; Cytomegalovirus (CMV); Everolimus; Mammalian target of rapamycin (mTOR) inhibitors; Sirolimus

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR;

ANTIVIRAL ACTIVITY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; SIROLIMUS;

EID: 84862290097     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824810e6     Document Type: Review

References (79)

1. Freeman RB Jr. The 'indirect' effects of cytomegalovirus infection. Am J Transplant 2009; 9: 2453.
2. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, et al. Severe cytomegalovirus infection in apparently immunocompetent patients: A systematic review. Virol J 2008; 5: 47.
3. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
4. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
5. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
6. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
7. Lautenschlager I, Helanterä I, Inkinen K, et al. Effect of CMV infection on chronic rejection of kidney transplants. In: Prösch S, Cinatl J, Scholz M, eds. New aspects of CMV-related immunopathology. Monograph virology. Basel, Karger 2003, p 10.
8. Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian Society of Transplantation Consensus Workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
9. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850.
10. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
11. Lorber MI, Mulgaonkar S, Butt KMH, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244.
12. Tedesco Silva H Jr, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007; 20: 27.
13. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
14. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036.
15. Kreis H, Cisterne J-M, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
16. Tedesco SilvaHJr, Cibrik D, Johnston T, et al. Everolimus plus reducedexposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401.
17. Vítko Š, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
18. Moorman NJ, Shenk T. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol 2010; 84: 5260.
19. Webster AC, Lee VWS, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and metaanalysis of randomized trials. Transplantation 2006; 81: 1234.
20. Ferrer IR, Araki K, Ford ML. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011; 11: 654.
21. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11: 1845.
22. Razonable RR. Strategies for managing cytomegalovirus in transplant recipients. Expert Opin Pharmacother 2010; 11: 1983.
23. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation.NEngl J Med 2007; 357: 2562.
24. San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47: 875.
25. Basic-Jukic N, Kes P, Bubic-Filipi LJ, et al. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation? Transplant Proc 2005; 37: 850.
26. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
27. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
28. European Mycophenolate Mofetil Cooperative Study Group. Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
29. Hernández D, Miquel R, Porrini E, et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007; 84: 706.
30. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
31. Kletzmayr J, Kotzmann H, Popow-Kraupp T, et al. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325.
32. Sagedal S, Hartmann A, Rollag H. The impact of early cytomegalovirus infection and disease in renal transplant recipients. Clin Microbiol Infect 2005; 11: 518.
33. O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008; 111: 1816.
34. van den Hoogen M, Hilbrands L. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2008; 358: 2519. (Pubitemid 351793043)
35. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
36. Glotz D, Charpentier B, Abramovicz D, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010; 89: 1511.
37. Fortun J, Martin-Davila P, Pascual J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 2010; 12: 397.
38. Tedesco-Silva H, Johnston T, Kim YS, et al. Everolimus-treated renal transplant patients have a lower incidence of CMV and BKV: Results from a multicenter, prospective study. Am J Transplant 2010; 10(suppl 4): 509, 1659 (abstract).
39. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453.
40. Vítko Š, Margreiter R,WeimarW, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532.
41. Ozaki KS, Câmara NOS, Nogueira E, et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transplant 2007; 21: 675.
42. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurininhibitor- free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837.
43. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115.
44. Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010; 23: 1084.
45. Boudreault AA, Xie H, Rakita RM, et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis 2011; 13: 244.
46. Guba M, Pratschke J, Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175.
47. Kudchodkar SB, Yu Y, Maguire TG, et al. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol 2004; 78: 11030.
48. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023.
49. Clippinger AJ, Maguire TG, Alwine JC. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol 2011; 85: 3930.
50. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T cell differentiation. Nature 2009; 460: 108.
51. Ferrer IR, Wagener ME, Robertson JM, et al. Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol 2010; 185: 2004.
52. Déchanet J, Merville P, Lim A, et al. Implication of FC T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103: 1437.
53. Halary F, Pitard V, Dlubek D, et al. Shared reactivity of VC2neg FC T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 2005; 201: 1567.
54. Li H, Pauza CD. Rapamycin increases the yield and effector function of human FC T cells stimulated in vitro. Cancer Immunol Immunother 2011; 60: 361.
55. Säemann MD, Haidinger M, Hecking M, et al. The multifunctional role of mTOR in innate immunity: Implications for transplant immunity. Am J Transplant 2009; 9: 2655.
56. Weichhart T, Costantino G, Poglitsch M, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: 565.
57. Lambert SL, Martinez OM. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 2007; 179: 8225.
58. Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008; 13: 563.
59. Renneson J, Dutta B, Goriely S, et al. IL-12 and type I IFN response of neonatal myeloid DC to human CMV infection. Eur J Immunol 2009; 39: 2789.
60. Dalod M, Salazar-Mather TP, Malmgaard L, et al. Interferon A and interleukin 12 responses to viral infections: Pathways regulating dendritic cell cytokine expression in vivo. J Exp Med 2002; 195: 517.
61. Isaacson MK, Juckem LK, Compton T. Virus entry and innate immune activation. Curr Top Microbiol Immunol 2008; 325: 85.
62. Kotenko SV, Saccani S, Izotova LS, et al. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci USA 2000; 97: 1695.
63. Moutaftsi M, Mehl AM, Borysiewicz LK, et al. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 2002; 99: 2913.
64. Hoffmann TW, Halimi JM, Büchler M, et al. Association between a polymorphism in the IL-12p40 gene and cytomegalovirus reactivation after kidney transplantation. Transplantation 2008; 85: 1406.
65. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840.
66. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet 2011; 377: 1256.
67. Büchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522.
68. Viganò M, Dengler T, Mattei MF, et al. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: A randomized, multicenter study. Transpl Infect Dis 2010; 12: 23.
69. Trotter JF, Wallack A, Steinberg T. Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper. Transpl Infect Dis 2003; 5: 174.
70. Margreiter R,Klempnauer J, Neuhaus P, et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial. Am J Transplant 2008; 8: 1480.
71. Kanter J, Pallardó L, Gavela E, et al. Cytomegalovirus infection renal transplant recipients: Risk factors and outcome. Transplant Proc 2009; 41: 2156.
72. Bataille S, Moal V, Gaudart J, et al. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression. Transpl Infect Dis 2010; 12: 480.
73. Torre-Cisneros J, Fortun J, Aguado JM, et al. Documento de consenso GESITRA-SEIMC sobre prevención y tratamiento de la infección por citomegalovirus en pacientes transplantados EConsensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients. Enferm Infecc Microbiol Clin 2005; 23: 424.
74. Charpentier B, Groth CG, Bäckman L, et al. Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: The Sirolimus European Renal Transplant Study. Transplant Proc 2003; 35(suppl 3A): 58S.
75. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883.
76. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/ sirolimus in renal transplantation: Three-year analysis. Transplantation 2006; 81: 845.
77. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332.
78. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very lowexposure cyclosporine a in de novo kidney transplantation: A multicenter, randomized, controlled trial. Transplantation 2009; 88: 1194.
79. Bertoni E, Salvadori M. Cyclosporine (CYA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC-MPS (M). J Am Soc Nephrol 2010; 21: 102A, SA-FC449 (abstract).